Mentions
Extended reach
Total likes
Video views
AI synopsis
The group demonstrates strong agreement and high interest through statements like 'ApoB is the primary causal driver of atherosclerosis' and mentions of new research, while engaging deeply by questioning relationships between measurements and discussing studies. The tone and context reflect a shared recognition of the publication's significant potential to shift cardiovascular risk assessment paradigms.
Most discussions strongly support the article's premise that apoB is a superior marker for cardiovascular risk, as evidenced by phrases like 'ApoB is not a weak risk factor' and 'most evidence shows highest CVD risk with high ApoB.'
Participants show high curiosity and engagement with the topic, referencing recent studies, debates, and asking specific questions about measurements and implications.
Many posts analyze and critique the research, with some providing detailed comments, referencing other research, and debating the significance of apoB versus LDL-C, indicating deep involvement.
The discussions highlight that the publication could influence clinical practices and understanding, emphasizing its importance and the revolutionary potential of apoB as a marker.
My critique of apoB, from Alan's excellent review. There is 1 apoB/particle-in his example, 84 LDL and 9 VLDL- i.e. 90% apoB is LDL. If VLDL/Lp(a) is ⏫ then apoB/CV risk will be ⏫. If normal, you get no/minimal info for the $. Key is lipid panel+Lp(a) https://t.co/NzwYVMwF8R https://t.co/AV47vVib7y https://t.co/UGufLBmbm5
@GaneshMuthappan @ianriddockmd @Drlipid https://t.co/mzxa7l5egc.
Great paper on the superiority of ApoB as a cardiovascular risk marker (vs LDL cholesterol level) https://t.co/0ubSz0Bud0
@twitevit @ProfTimNoakes Actually, ApoB is not a weak risk factor. It’s the primary causal driver of atherosclerosis and predicts ASCVD risk more strongly than LDL-C or even non-HDL-C. https://t.co/Bb3yoHBDTL It is normally distributed in the population, but that’s irrelevant. What matters is that risk
Your Doctor is Wrong About Cholesterol, Apo B and Plaque https://t.co/O8WHWRYijy via @YouTube
@realDaveFeldman @AdrianSotoMota @BudoffMd Did the study collect ApoB data? Also there seems to be a lot of confusion about LDL-c vs. LDL-p vs. ApoB. (FYI only.) https://t.co/mndcYxljMr
ApoB plays a critical role in atherosclerosis development. Monitoring apoB levels offers a more accurate assessment of cardiovascular risk than traditional cholesterol markers, highlighting the importance of lipoprotein…
This video explains why apolipoprotein B is a superior indicator of cardiovascular risk compared to LDL cholesterol, emphasizing its role in identifying atherogenic particles and improving risk assessment for heart…
High cholesterol prompted a reevaluation of habits and diet. This video explains effective lifestyle changes to lower cholesterol naturally, emphasizing the importance of diet and the role of apolipoprotein B as a more…
This episode explores apolipoprotein B (apoB), a better indicator of atherosclerosis risk than traditional cholesterol tests, explaining its structure, function, and significance in cardiovascular health.
Dive into the role of ApoB in cardiovascular health and its impact on longevity. Understanding ApoB's involvement in arterial plaque formation and risk assessment clarifies its significance beyond traditional…
Learn about Apolipoprotein B and its significance in cardiovascular health, as it offers a clearer risk assessment than traditional cholesterol measures and is key to understanding longevity and heart disease prevention.
Learn about ApoB levels, a crucial biomarker for heart health. ApoB particles are better indicators of atherosclerosis risk than traditional cholesterol measures. A simple blood test can reveal important insights to…
Learn the importance of ApoB levels as a risk indicator for cardiovascular disease, highlighting their role in atherosclerosis and the limitations of traditional cholesterol measures for assessing heart health.
Welcome back to our podcast. In this episode, we discuss recent cardiac screening results and the importance of interpreting blood tests like LDL-C, ApoB, BMI, and fasting glucose to assess cardiovascular risk and…
Relevant papers: https://t.co/EHQvJo65Gf https://t.co/0pBoJ1ekh1 https://t.co/aMoHkQtYra https://t.co/uZIAJG6ZL1 https://t.co/sjGgYSZS3c
@ChristofferBN @Pl4ntbased Pts w/ FH have an overproduction/turnover issue (similar to LMHR). Loss of LDLr does not alone explain such extreme elevations in LDLc bcus most is cleared through nonspecific receptors when LDLr is saturated (high affinity low capacity system) https://t.co/jF0q2MZMf3
Interesting Study from 2022 on the benefits of testing for apob over just LDL cholesterol. https://t.co/paKZUi9q1T
@twitevit @ProfTimNoakes Actually, ApoB is not a weak risk factor. It’s the primary causal driver of atherosclerosis and predicts ASCVD risk more strongly than LDL-C or even non-HDL-C. https://t.co/Bb3yoHBDTL It is normally distributed in the population, but that’s irrelevant. What matters is that risk
@BroChillerman @DrPlantel Large amount of evidence in all lines of studies showing highest CVD risk with high ApoB over time, irrespective of particle size or "ratios". https://t.co/ehZuhD2Am1
https://t.co/Vqii3gXd6k
Your Doctor is Wrong About Cholesterol, Apo B and Plaque https://t.co/O8WHWRYijy via @YouTube
@theproof @Drlipid "Lp(a) appears to influence ASCVD risk independent of LDL-c or total ApoB" https://t.co/mzxa7l5egc
@Drlipid @johnrroberts3 @theproof "Lp(a) appears to influence ASCVD risk independent of LDL-c or total ApoB" https://t.co/mzxa7l5egc
@ethanjweiss @theproof @Drlipid @Lipoprotein @realDaveFeldman LDLr mutations still need a 2nd hit (incr VLDL production w intact turnover) to have FH. Most people with LDLR mutations don’t develop FH. Sniderman et al describe how LDLr alone can’t account for the very incr LDLC in FH. LMHR are no different https://t.co/cLeRsHP1XG
@ethanjweiss @realDaveFeldman @And41111 @PeterFaberSP @nicknorwitz https://t.co/cLeRsHP1XG The model they propose I don’t think is new. And LMHR still very much mimics metabolically healthy FH pts with ⬆️VLDL secretion, efficient turnover, and ⬇️LDL clearance.
@Alicewants2know @MohammedAlo https://t.co/A48IyjeN7e
@realDaveFeldman @AdrianSotoMota @BudoffMd Did the study collect ApoB data? Also there seems to be a lot of confusion about LDL-c vs. LDL-p vs. ApoB. (FYI only.) https://t.co/mndcYxljMr
@onphel @zoeharcombe https://t.co/VFWeTdzipw Here’s the update to that same article. Anyway if you want to learn more about bookmakers particularly lipids You can start here https://t.co/QKkEnAAzTd. Or bury your head in the sand
@MasalaFry69 @DrNadolsky My point was apoB particles size better indicator of risk than ldl cholesterol. This is what I was thinking.. https://t.co/xkB5Sa9erx.
@GaneshMuthappan @ianriddockmd @Drlipid https://t.co/mzxa7l5egc.
@soyboy86 ApoB je ključna mera za zdravstveni rizik https://t.co/pOxoRJWB5b
@MasalaFry69 @BoaterOwl @Aybayapp @SBakerMD https://t.co/9MbqKSkzt9
@BoaterOwl @MasalaFry69 @Aybayapp @SBakerMD https://t.co/9MbqKSkzt9
@JoshuaRollins33 @daedalus0101 @podclipsapp @Drlipid @MohammedAlo @nationallipid @society_eas @TheFHFoundation @fhpatienteurope This was a good read. https://t.co/369dZ3M4nn
RT @Lpa_Doc: My critique of apoB, from Alan's excellent review. There is 1 apoB/particle-in his example, 84 LDL and 9 VLDL- i.e. 90% apoB i…
My critique of apoB, from Alan's excellent review. There is 1 apoB/particle-in his example, 84 LDL and 9 VLDL- i.e. 90% apoB is LDL. If VLDL/Lp(a) is ⏫ then apoB/CV risk will be ⏫. If normal, you get no/minimal info for the $. Key is lipid panel+Lp(a) https://t.co/NzwYVMwF8R https://t.co/AV47vVib7y https://t.co/UGufLBmbm5
https://t.co/IxMi4OD1dx
@TyRBeal @LDLSkeptic @BenBikmanPhD @realDaveFeldman Does that apoB always correlate with high LDL-c? I did a quick Google search for an answer to my question, and this linked study suggests that it doesn't. Have you seen other research that contradicts this study? https://t.co/7NzsyEQiMW .
@jdmiller_ @PatrickElliott0 @NutritionMadeS3 @mak_sysepi @POhukainen @mendel_random Here’s a recent review. #apob https://t.co/0u02hdwN5w https://t.co/WND4gNJBfv
We provide a framework for healthcare providers to understand why apoB is a more accurate marker of CV risk than LDL-C or non-HDL-C. @tamaranephro #AHAJournals https://t.co/7z2028wOqs
Great paper on the superiority of ApoB as a cardiovascular risk marker (vs LDL cholesterol level) https://t.co/0ubSz0Bud0
Good review of apoB physiology by Glavinovic @ThanassoulisMD de Graaf, Couture, Hegele, & @AllanSniderman https://t.co/Ts7lohd6HG